AR and prostate cancer: Thus, we determined the impact of NXP800, its inactive chemical control CCT365248, and also enzalutamide, on transfected AR-FL or AR-V7 transactivation of a PSA-ARE3-driven luciferase reporter assay system in AR negative PC3 prostate cancer cells (Fig. 2D).